PTPRZ1 and Alzheimer disease: This study provides for the first time convincing evidence that RPTPβ/ζ inhibition with MY10 significantly reduces Aβ plaque formation, which seems related to the capacity of MY10 to regulate glial responses and the proinflammatory signal characteristic of AD, and to modulate the expression of Aβ aggregate-degrading enzymes.